Stock 301333 R&G PHARMASTUDIES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials R&G PharmaStudies Co., Ltd.

Equities

301333

CNE100005K44

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
46.73 CNY -3.63% Intraday chart for R&G PharmaStudies Co., Ltd. -3.41% -27.53%
Apr. 21 R&G PharmaStudies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 4,940 6,190 4,486 - -
Enterprise Value (EV) 1 4,940 6,190 4,486 4,486 4,486
P/E ratio 23.2 x 31 x 25.6 x 19.2 x 16.4 x
Yield - 0.31% 5.2% 6.1% -
Capitalization / Revenue - 8.58 x 5.2 x 4.29 x 3.6 x
EV / Revenue - 8.58 x 5.2 x 4.29 x 3.6 x
EV / EBITDA - 28.5 x 21.6 x 16.7 x 14 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - 3.54 x 2.46 x 2.23 x 1.89 x
Nbr of stocks (in thousands) 96,000 96,000 96,000 - -
Reference price 2 51.46 64.48 46.73 46.73 46.73
Announcement Date 4/24/23 4/21/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 721.4 863.5 1,045 1,248
EBITDA 1 - 217.1 207.9 268 320
EBIT 1 - 182.5 205 270 324.3
Operating Margin - 25.3% 23.74% 25.82% 25.99%
Earnings before Tax (EBT) 1 - 182.5 209 273 334.3
Net income 1 113.6 162.5 174.8 234.5 273.8
Net margin - 22.53% 20.25% 22.43% 21.95%
EPS 2 2.220 2.080 1.825 2.440 2.850
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - 0.2000 2.430 2.850 -
Announcement Date 4/24/23 4/21/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - 9.75% 10.1% 11.8% 11.5%
ROA (Net income/ Total Assets) - - 8.15% 9.88% 10.2%
Assets 1 - - 2,145 2,374 2,687
Book Value Per Share 2 - 18.20 19.00 20.90 24.70
Cash Flow per Share 2 - 2.010 1.700 2.610 2.970
Capex 1 - 19.9 10 10 -
Capex / Sales - 2.75% 1.16% 0.96% -
Announcement Date 4/24/23 4/21/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
46.73 CNY
Average target price
65 CNY
Spread / Average Target
+39.10%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
R&G PHARMASTUDIES CO., LTD. Stock R&G PharmaStudies Co., Ltd.
-27.53% 621M
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+20.68% 85.55B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-29.31% 70.07B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+9.23% 29.06B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-8.63% 17.51B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+2.14% 17.39B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+0.39% 15.38B
REDE D'OR SÃO LUIZ S.A. Stock Rede D'Or São Luiz S.A.
+6.47% 13.4B
NATERA, INC. Stock Natera, Inc.
+68.09% 12.87B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+6.43% 12.77B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. 301333 Stock
  4. Financials R&G PharmaStudies Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW